Navigation Links
Publication in peer-reviewed journal highlights RESPeRATE as effective hypertension treatment
Date:4/22/2009

New York, N.Y.April 22, 2009InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that RESPeRATEthe only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertensionis highlighted as an effective treatment for high blood pressure in the April issue of the Journal of the American Academy of Nurse Practitioners.

The article, written by Elayne DeSimone, ANP, PhD, encourages the entire clinical community, in particular nurse practitioners and physician assistants, to provide individual attention and discuss non-traditional methods when treating patients who suffer from hypertension.

"A patient needs to fully understand his or her individual degree of risk, as well as the consequences of remaining untreated, to feel motivated to take an active part in their healthcare and be compliant with treatment," says DeSimone. "Seven out of 10 patients are not able to achieve their lower blood pressure goals with medication alone, and it is critically important to inform patients of both drug and non-drug treatment options to effectively treat both hypertension and its potential co-morbidities."

In the article, DeSimone highlights the impact of the nurse practitioner as an important source of information and empowerment for the patient. Early detection, monitoring and treatment of hypertension can dramatically reduce the number of hypertensive Americans and have a substantial impact on its associated consequences, both clinically and economically. Promotion of patient awareness and communication, coupled with a blend of drug and non-drug therapies can maximize the effect of a blood pressure treatment regimen.

Diet, exercise and adjunctive treatments are discussed as a way to help patients develop a new routine that fits into their lifestyles and improve treatment compliance. RESPeRATE is highlighted by DeSimone as a treatment that has been proven in multiple clinical studies to produce a significant and lasting decrease in blood pressure, averaging a reduction of 14 points systolic and 8 points diastolic.

"This most recent acknowledgement of RESPeRATE as an effective treatment option for hypertension adds to a growing body of support within the clinical community," says Erez Gavish, president and CEO, InterCure. "Nurse practitioners are vital in providing the best care possible to patients and we hope that these essential caretakers will choose to educate patients about the importance of non-drug therapies such as RESPeRATE."


'/>"/>

Contact: Lisa Mokaba
intercure@schwartz-pr.com
781-684-0770
Schwartz Communications
Source:Eurekalert

Related medicine news :

1. Open access to health research publications
2. Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
3. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
4. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
5. Telemedicine publication expands coverage
6. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
7. Fry Construction Is Featured in Key Industry Publication
8. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
9. Nature publication on pain research
10. Bojan M. Kuure Recognized by Strathmores Whos Who Worldwide Publication
11. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies , ... the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice President ... and sales network, direct the efforts of the surgical sales teams, manage contractual ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
Breaking Medicine Technology: